Advertisement

Clinical Pharmacokinetics

, Volume 28, Issue 6, pp 458–470 | Cite as

Clinical Pharmacokinetics of Lansoprazole

  • B. Delhotal Landes
  • J. P. Petite
  • B. Flouvat
Review Article Drug Disposition

Summary

Lansoprazole, a benzimidazole derivative with antisecretory and antiulcer activities, inhibits the acid pump activity at the final stage of the enzyme process and therefore reduces the acid secretion of parietal cells. Lansoprazole is converted to active metabolites in the acid environment of these cells. It is rapidly absorbed from a gastric acid-resistant formulation and is approximately 97% bound in human plasma.

Single dose pharmacokinetics of lansoprazole appear to be linear over the range from 15 to 60mg. Food and time of dose influence absorption after single doses, but do not modify the antisecretory effect of multiple doses. Lansoprazole is extensively metabolised following oral administration into sulphone and 5-hydroxylated metabolites by the cytochrome P450 enzymes CYP3A4 and CYP2C18. Two other metabolites have been identified in plasma: sulphide and hydroxylated sulphone.

Mean plasma elimination half-life (t½) is between 1.3 and 2.1 hours in healthy volunteers. 15 to 23% of the total dose is found in urine as free and conjugated hydroxylated metabolites, while unchanged lansoprazole is not detected. The pharmacokinetic profile of the drug is not modified by multiple administration. In healthy elderly volunteers, area under the plasma concentration-time curve (AUC) and t½ are significantly greater after single administration than that in young volunteers; accumulation from repeated daily administration occurs to the same extent as in young volunteers.

Renal failure has no influence on the pharmacokinetics of lansoprazole, but severe hepatic failure causes a significant decrease in clearance and an increase in the AUC and t½ of lansoprazole. This is accompanied by modifications in the AUC of metabolites, but severe hepatic failure has minimal effect on accumulation of the drug after multiple administration. The pharmacokinetics of lansoprazole in patients with acid-related disorders do not differ from those in healthy volunteers. Studies of interactions of lansoprazole with warfarin, prednisone, theophylline, phenazone (antipyrine), diazepam, phenytoin and oral contraceptives suggest minimal risk of any clinically significant interaction.

Keywords

Adis International Limited Theophylline Omeprazole Ranitidine Lansoprazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44(2): 225–50PubMedCrossRefGoogle Scholar
  2. 2.
    Nagaya H, Inatomi N, Satoh H. Effect of repeated administration of AG-1749 (lansoprazole) on acid secretion, serum gastrin level and pharmacokinetics of AG-1749 in Heidenhain Pouch Dogs. Jpn Pharmacol Ther 1991; 19(2): 99–103Google Scholar
  3. 3.
    Aoki I, Okumura M, Yashiki T. High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. J Chromatogr Biomed Appl 1991; 571(1–2): 283–90Google Scholar
  4. 4.
    Delhotal Landes B, Miscoria G, Flouvat B. Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1992; 577: 117–22CrossRefGoogle Scholar
  5. 5.
    Hussein Z, Granneman GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 391–8PubMedCrossRefGoogle Scholar
  6. 6.
    Tateno M, Nakamura N. Phase I study of lansoprazole (AG-1749) antiulcer agent: capsule form. Rinsho Iyaku 1991; 7: 51–62Google Scholar
  7. 7.
    Flouvat B, Delhotal Landes B, Dellatolas F, et al. Pharmacocinétique du Lansoprazole ou AG-1749 ou RU 49749 chez le sujet sain. Symposium LANZOR, 1991 Apr 12; ParisGoogle Scholar
  8. 8.
    Delhotal Landes B, Cournot A, Vermerie N, et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991; Special issue no. III: 315–20Google Scholar
  9. 9.
    Flouvat B, Delhotal Landes B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467–9PubMedCrossRefGoogle Scholar
  10. 10.
    Hogan DL, Koss MA, Peitelberg S, et al. Single and repetitive administration of lansoprazole effects on gastric acid secretion, pharmacokinetics and serum gastrin in old vs young subjects [abstract]. Gastroenterology 1991; 100 (5 Pt 2): A84Google Scholar
  11. 11.
    Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH comparison between morning dosing and evening dosing [abstract]. Gastroenterology 1992; 102 (4 Pt 2): A84Google Scholar
  12. 12.
    Moules I, Garrett A, Blockleband D, et al. Gastric acid inhibition by the proton pump inhibitor lansoprazole is unaffected by food. Br J Clin Res 1993; 4: 153–61Google Scholar
  13. 13.
    Chassard D, Schlander M, Douin MJ, et al. Study of tolerance, pharmacokinetics and pharmacodynamics of single rising intravenous doses of lansoprazole [abstract]. Eur J Drug Metab Pharmacokinet 1993; 18(1): 109Google Scholar
  14. 14.
    Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 1990 Mar; 252(3): 1289–95PubMedGoogle Scholar
  15. 15.
    Delhotal Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993; 45: 367–71PubMedCrossRefGoogle Scholar
  16. 16.
    Pichard L, Curi-Pedrosa R, Bonfils C, et al. Oxidative metabolism of lansoprazole by human liver cytochrome P450S. Mol Pharmacol 1995; 47: 410–8PubMedGoogle Scholar
  17. 17.
    Coste T, Logeais C, Delhotal Landes B, et al. Pharmacokinetics of lansoprazole after repeated administration in cirrhosis patients [abstract]. Gastroenterology 1993; 104 (4 Pt 2): A59Google Scholar
  18. 18.
    Braeckman RA, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on warfarin pharmacokinetics and anticoagulation effect in healthy subjects. Pharm Res 1991; 8 (10 Suppl.); S295Google Scholar
  19. 19.
    Cavanaugh JH, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on steady state warfarin metabolism [abstract]. Gastroenterology 1991; 100 (5 Pt 2): A40Google Scholar
  20. 20.
    Cavanaugh JH, Locke C, Karol M. Lack of interaction of lansoprazole or omeprazole with prednisone [abstract]. Am J Gastroenterol 1993; 88(9): 1589Google Scholar
  21. 21.
    Granneman G, Winters EP, Locke CS, et al. Lack of effect of concomitant lansoprazole on steady state theophylline pharmacokinetics [abstract]. Gastroenterology 1991; 100 (5 Pt 5): A75Google Scholar
  22. 22.
    Roux A, Naline R, Molinier P, et al. Effect of lansoprazole and omeprazole on the metabolism of theophylline and antipyrine in man [abstract]. Eur J Drug Metab Pharmacokinet 1993; 18(1): 125Google Scholar
  23. 23.
    Cavanaugh JH, Park YK, Awnin MM, et al. Effect of lansoprazole on antipyrine and IBG pharmacokinetics [abstract]. Gastroenterology 1991; 100 (5 Pt 2): A40Google Scholar
  24. 24.
    Lefebvre RA, Flouvat B, Karolak Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52(5): 458–63PubMedCrossRefGoogle Scholar
  25. 25.
    Gerloff J, Barth H, Mignot A, et al. Does the proton pump inhibitor lansoprazole interact with antacids? Naunyn Schmiedebergs Arch Pharmacol 1993; 347: R31Google Scholar
  26. 26.
    Karol M, Mukherji D, Cavanaugh J. Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects [abstract]. Gastroenterology 1994; 106(4): A104Google Scholar
  27. 27.
    Fuchs W, Sennewld R, Klotz V. Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 1994; 38: 376PubMedCrossRefGoogle Scholar
  28. 28.
    Loght H, Andrieu J, Bognel JC, et al. Lansoprazole versus ranitidine dans le traitement des ulcères duodénaux: resultats d’un essai multicentrique controle, randomissé, en double insu sur groupes parallèles. Med Chir Dig 1991; 19: 251–5Google Scholar
  29. 29.
    Hawkey CJ, Long RG, Bardhan KD, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993; 34: 1458–62PubMedCrossRefGoogle Scholar
  30. 30.
    Londong W, Barth H, Dammann HG, et al. Dose related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther 1991; 5: 245–54PubMedCrossRefGoogle Scholar
  31. 31.
    Petite JP, Slama JL, Light H, et al. Comparaison du Lansoprazole (30mg) et de 1’Oméprazole (20mg) dans le traitement de l’ulcère duodénal. Gastroenterol Clin Biol 1993; 17: 334–40PubMedGoogle Scholar
  32. 32.
    Louw JA, Van Rensburg C, Simjee AE, et al. Lansoprazole versus omeprazole in duodenal ulcer healing [abstract]. SAMJ 1993; 83: 777Google Scholar
  33. 33.
    Colin R, Laffineur G, Lemaire M. Efficacité comparée du Lansoprazole et de la Ranitidine dans le traitement de l’ulcère gastrique en poussée: etude multicentrique en double aveugle [abstract]. Gastroenterol Clin Biol 1993; 17: A218Google Scholar
  34. 34.
    Florent Ch, Forestiers S, Joubert-Collin M. Lansoprazole versus omeprazole: efficacy and safety in acute gastric ulcer [abstract]. Gastroenterology 1993; 104 (4 Pt 2): A80Google Scholar
  35. 35.
    Petite JP, Salducci J, Evreux M, et al. Lansoprazole versus ranitidine dans le traitement de l’oesophagite peptique [abstract]. Gastroenterol Clin Biol 1990; 14: A108Google Scholar
  36. 36.
    Metz D, Pisegna J, Ringham G, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 245–56PubMedCrossRefGoogle Scholar
  37. 37.
    Mignon M, Hochlaf S, Forestiers S, et al. Effet dose-reponse du Lansoprazole chez les malades atteints d’un syndrome de Zollinger-Ellison. Gastroenterol Clin Biol 1994; 18: 13–6PubMedCrossRefGoogle Scholar
  38. 38.
    Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther 1993; 7: 56–60PubMedCrossRefGoogle Scholar
  39. 39.
    Dammann HG, Von Zur Muhlen A, Balks HJ, et al. The effects of lansoprazole, 30 or 60mg daily, on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993; 7: 191–6PubMedCrossRefGoogle Scholar
  40. 40.
    Gaetani M, Buratti P, Pasquali R, et al. Chronic oral administration with lansoprazole does not affect gonadotropin pulsatile pattern in healthy males [abstract]. Gastroenterology 1993; 104: A84Google Scholar
  41. 41.
    Solcia E, Villani L, Luinetti O, et al. Proton pump inhibitors, enterochromaffin-like cell growth and helicobacter pylori gastritis. Aliment Pharmacol Ther 1993; 7: 25–8PubMedCrossRefGoogle Scholar
  42. 42.
    Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35: 23–6PubMedCrossRefGoogle Scholar
  43. 43.
    Armstrong D, Viani F, Siegrist H, et al. Does omeprazole increase gastric bacterial counts, nitrite or total nitroso compounds in healthy subjects? [abstract] Gastroenterology 1992; 102: A34Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • B. Delhotal Landes
    • 1
  • J. P. Petite
    • 2
  • B. Flouvat
    • 1
  1. 1.Toxicology and Pharmacokinetics LaboratoryAmbroise Paré HospitalBoulogneFrance
  2. 2.Department of HepatogastroenterologyBroussais HospitalParisFrance

Personalised recommendations